Use of a Biological Lens of Amniotic Membrane (LV-Visio-AMTRIX) in the Treatment of Treatment-Resistant Keratitis

Phase 2TerminatedNCT05250583

TBF Genie Tissulaire5 enrolled

Overview

The purpose of this open, mono center trial is to assess the impact of the use of an amniotic membrane on the healing of a keratitis resistant to medical treatment.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Keratitis

Interventions

LV-Visio-AMTRIXBIOLOGICAL

Chemically-treated, viro-inactivated, freeze-dried and irradiated allograft placed by the investigator during patients' hospital visit

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female; age between 18 and 65 years. * Patient with non-infectious keratitis resistant to medical treatment for more than 15 days or recurrent after healing treatment. * Patient with quantitative and qualitative score for inflammatory ocular signs \> 20. * Patient with Oxford grade \> 2. * Informed and consenting patient with a relative or friend available to instill eye drops if necessary. * Patient affiliated to a social security system or beneficiary of such a system. Exclusion Criteria: * Patient with active infectious keratitis (bacterial, parasitic or viral). * Patient with allergy to Oxybuprocaine or Tetracaine eye drops, to ester type local anesthetics and to fluorescein. * Current contact lens wear, including scleral lenses. * NSAID eye drops and any drops containing preservatives. * Antibiotic, anti-viral, anti-parasitic eye drops. * Patient with identified causes for the keratitis for which discontinuation of medical treatment beneficial. * Ocular surgery in the 3 months preceding the inclusion in the study. * Monophtalmic patient. * Person deprived of liberty by a judicial or administrative decision. * Adult subjected to a legal protection measure or unable to express his/her consent.

Locations (1)

CHU de Saint-Etienne Hôpital Nord

Saint-Priest-en-Jarez, France

Outcomes

Primary Outcomes

Keratitis healing within 15 days after the beginning of the treatment

Keratitis observed under slit lamp using fluorescein instillation. Keratitis considered healed if epithelialization of more than 50% and/or Oxford \< grade 2

Time frame: 15 days

Secondary Outcomes

Stable or decreased score for inflammatory and clinical signs of the ocular surface

Composite score for inflammatory and clinical signs of the ocular surface on 66 points. Duration and intensity are evaluated for secretion, dry eyes, tearing, foreign body sensation, fluctuating vision, photophobia, burning sensation and lids edema. Duration is evaluated from a scale from 0: never to 4: all the time. Intensity is evaluated from a scale from 0: slight to 2: severe. Localization and intensity are evaluated for conjunctival edema, conjunctival redness and neovascularization. Localization is evaluated on a scale from 0: no reaction to 4: reaction present in the whole eye.

Time frame: 1 day, 3 days, 5 days, 7 days, 10 days, 15 days, 30 days, 45 days

Stabilisation or decrease of pain evaluated on visual analog scale

Visual Analog Scale (VAS) on 10 points from 0: no pain to 10: worst imaginable pain

Time frame: 1 day, 3 days, 5 days, 7 days, 10 days, 15 days, 30 days, 45 days

Preservation of epithelialization

Preservation of new epithelialization evaluated under slit lamp using fluorescein instillation and Oxford grading system

Time frame: 15 days, 30 days, 45 days

Change in eye dryness

Eye dryness evaluated by the Ocular Surface Disease Index (OSDI) (0-12 = normal; 13-22 = mild dry eye; 23-32 = moderate dry eye; \>33 = severe dry eye)

Time frame: 15 days, 30 days, 45 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.